2 weeks Ago By Defense World Staff
HighTower Advisors LLC raised its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 7.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,542 shares of the biotechnology company’s stock after acquiring an additional 400 shares during the period.
HighTower Advisors LLC’s holdings in Ligand Pharmaceuticals were worth $594,000 at the end of the most recent reporting period. Other large investors have also recently modified their holdings of the company. Thrivent Financial for Lutherans raised its stake in Ligand Pharmaceuticals by 2.
2% in the third quarter. Thrivent Financial for Lutherans now owns 15,084 shares of the biotechnology company’s stock valued at $1,510,000 after purchasing an additional 329 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Ligand Pharmaceuticals in the 3rd quarter worth $329,000.
Charles Schwab Investment Management Inc. raised its position in shares of Ligand Pharmaceuticals by 5.5% during the 3rd quarter.
Charles Schwab Investment Management Inc. now owns 163,924 shares of the biotechnology company’s stock valued at $16,407,000 after buying an additional 8,584 shares in the last quarter. FMR LLC lifted its holdings in shares of Ligand Pharmaceuticals by 550.
5% during the 3rd quarter. FMR LLC now owns 12,749 shares of the biotechnology company’s stock worth $1,276,000 after acquiring an additional 10,789 shares during the last quarter. Finally, Townsquare Capital LLC grew its position in Ligand Pharmaceuticals by 11.
8% in the third quarter. Townsquare Capital LLC now owns 29,813 shares of the biotechnology company’s stock worth $2,984,000 after acquiring an additional 3,140 shares in the last quarter. Institutional investors own 91.
28% of the company’s stock. Ligand Pharmaceuticals Stock Down 1.9 %Shares of LGND stock opened at $107.
62 on Friday. The business’s fifty day moving average is $114.20 and its 200 day moving average is $112.
07. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of 42.
88 and a beta of 1.12. Ligand Pharmaceuticals Incorporated has a twelve month low of $67.
72 and a twelve month high of $129.90. Insider Transactions at Ligand PharmaceuticalsIn related news, CFO Octavio Espinoza sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction dated Tuesday, March 4th.
The stock was sold at an average price of $115.03, for a total value of $575,150.00.
Following the completion of the sale, the chief financial officer now directly owns 18,879 shares in the company, valued at approximately $2,171,651.37. This trade represents a 20.
94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.
90% of the stock is owned by insiders. Analysts Set New Price TargetsA number of equities research analysts have weighed in on the company. Benchmark restated a “buy” rating and set a $135.
00 price target on shares of Ligand Pharmaceuticals in a research report on Monday, December 23rd. Royal Bank of Canada boosted their target price on Ligand Pharmaceuticals from $141.00 to $143.
00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating on shares of Ligand Pharmaceuticals in a research note on Wednesday, December 11th. StockNews.
com raised shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 18th. Finally, Barclays upped their price objective on shares of Ligand Pharmaceuticals from $150.00 to $160.
00 and gave the company an “overweight” rating in a research note on Monday, December 16th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.
com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $147.00.View Our Latest Research Report on Ligand PharmaceuticalsAbout Ligand Pharmaceuticals (Free Report)Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.See AlsoFive stocks we like better than Ligand PharmaceuticalsBreakout Stocks: What They Are and How to Identify ThemMarketBeat Week in Review – 03/24 – 03/28How to Invest in Biotech StocksShould You Buy UPS Stock Now? Deep Dive Into Its 5-Year LowWhat Does a Stock Split Mean? 4 Healthcare Stocks With Massive Gains—and More to ComeWant to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report).
.
